Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly and Boehringer Ingelheim Pharmaceuticals have announced that Basaglar (insulin glargine injection 100 units/mL) is available by prescription in…
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Synjardy XR tablets for adults with type 2 diabetes.…
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
The Supervisory Board of Bayer has approved the reorganization proposed by the Board of Management, so that from January 1,…
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly reported that the Company’s Jardiance (empagliflozin) had reduced the risk of the…